Landos Biopharma is a clinical-stage biopharmaceutical company focused on the development of oral therapeutics for patients with certain immunology diseases. Co.'s main candidate is NX-13, an oral, gut-selective NLRX1 agonist. In addition to NX-13, Co. has several preclinical product candidates: LABP-73, an oral, small molecule NLRX1 pathway agonist for the treatment of asthma and Chronic Obstructive Pulmonary Disease; LABP-66, an oral, small molecule NLRX1 pathway agonist for the treatment of multiple sclerosis, and Alzheimer's disease; and LABP-69, an oral, small molecule PLXDC2 pathway agonist in development for the treatment of diabetic nephropathy and rheumatoid arthritis. The LABP YTD return is shown above.
The YTD Return on the LABP YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether LABP YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the LABP YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.
|